Sumitomo Mitsui Trust Group Inc. Has $20.40 Million Holdings in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Sumitomo Mitsui Trust Group Inc. decreased its stake in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 6.7% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,926,084 shares of the biotechnology company's stock after selling 138,966 shares during the period. Sumitomo Mitsui Trust Group Inc. owned 7.10% of Arcturus Therapeutics worth $20,397,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Byrne Asset Management LLC lifted its stake in shares of Arcturus Therapeutics by 89.8% during the first quarter. Byrne Asset Management LLC now owns 2,885 shares of the biotechnology company's stock valued at $31,000 after acquiring an additional 1,365 shares during the period. Virtus ETF Advisers LLC lifted its position in Arcturus Therapeutics by 38.8% during the 4th quarter. Virtus ETF Advisers LLC now owns 4,051 shares of the biotechnology company's stock valued at $69,000 after purchasing an additional 1,132 shares during the period. KLP Kapitalforvaltning AS acquired a new position in Arcturus Therapeutics in the fourth quarter valued at approximately $71,000. National Bank of Canada FI lifted its holdings in Arcturus Therapeutics by 639.6% in the fourth quarter. National Bank of Canada FI now owns 5,532 shares of the biotechnology company's stock valued at $94,000 after buying an additional 4,784 shares during the period. Finally, Kennedy Capital Management LLC lifted its holdings in Arcturus Therapeutics by 22.7% in the fourth quarter. Kennedy Capital Management LLC now owns 10,987 shares of the biotechnology company's stock valued at $186,000 after buying an additional 2,036 shares during the period. Institutional investors and hedge funds own 94.54% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on ARCT. HC Wainwright reissued a "buy" rating and issued a $60.00 price target on shares of Arcturus Therapeutics in a research note on Thursday, April 10th. Wall Street Zen lowered Arcturus Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday. BTIG Research set a $48.00 price target on shares of Arcturus Therapeutics and gave the company a "buy" rating in a research report on Monday, March 10th. Canaccord Genuity Group cut their price target on shares of Arcturus Therapeutics from $68.00 to $66.00 and set a "buy" rating on the stock in a research report on Tuesday, May 13th. Finally, Wells Fargo & Company cut their target price on shares of Arcturus Therapeutics from $50.00 to $45.00 and set an "overweight" rating on the stock in a report on Wednesday, May 14th. One research analyst has rated the stock with a sell rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $54.00.

Arcturus Therapeutics Stock Down 3.0%

Shares of ARCT traded down $0.42 during midday trading on Monday, hitting $13.36. The stock had a trading volume of 428,993 shares, compared to its average volume of 421,219. The company has a 50 day simple moving average of $12.48 and a two-hundred day simple moving average of $13.95. Arcturus Therapeutics Holdings Inc. has a twelve month low of $8.04 and a twelve month high of $25.88. The firm has a market cap of $362.32 million, a price-to-earnings ratio of -5.28 and a beta of 2.27. The company has a debt-to-equity ratio of 0.06, a current ratio of 5.64 and a quick ratio of 5.64.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The biotechnology company reported ($0.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.58) by $1.06. The firm had revenue of $29.38 million for the quarter, compared to analyst estimates of $25.64 million. Arcturus Therapeutics had a negative net margin of 47.47% and a negative return on equity of 27.41%. On average, analysts anticipate that Arcturus Therapeutics Holdings Inc. will post -2.22 EPS for the current year.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.